Culmerciclib
Sponsors
Second Affiliated Hospital, School of Medicine, Zhejiang University, Fudan University, Sun Yat-sen University, Shengjing Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions
Breast CancerEarly-Stage Breast CancerHER2 Low Breast CarcinomaHER2+ Advanced Breast CancerHR Positive, HER2 Positive Breast CancerHR+/HER2- Early Breast CancerHR-positive, HER2-negative Metastatic Breast Cancer With Brain MetastasesHormone Receptor-Positive Breast Cancer
Phase 2
Efficacy and Safety of Culmerciclib Plus Aromatase Inhibitors in a Response-Adapted Neoadjuvant Strategy for Highly Proliferative ER-Positive/HER2-Negative Breast Cancer
RecruitingNCT07616453
Start: 2026-05-06End: 2033-05-05Target: 45Updated: 2026-06-01
A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.
RecruitingNCT07666555
Start: 2026-06-06End: 2029-12-30Target: 98Updated: 2026-06-24
Culmerciclib in HR+/HER2+ Advanced Breast Cancer
RecruitingNCT07732491
Start: 2026-08-01End: 2035-12-31Target: 35Updated: 2026-07-29
Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain Metastases
Not yet recruitingNCT07745257
Start: 2026-08-28End: 2028-07-28Target: 40Updated: 2026-08-04
Culmerciclib Combined With Letrozole and Dual HER2 Blockade as Neoadjuvant Therapy for HR+/HER2+ Breast Cancer
Not yet recruitingNCT07795424
Start: 2026-09-01End: 2028-06-30Target: 33Updated: 2026-08-31
Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Not yet recruitingNCT07796880
Start: 2026-09-15End: 2033-03-15Target: 80Updated: 2026-09-10